The Journal of Physiological Sciences

, Volume 65, Issue 1, pp 25–35 | Cite as

Physiological significance of delayed rectifier K+ channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease

Review
First Online:
Received:
Accepted:

Abstract

T lymphocytes predominantly express delayed rectifier K+ channels (Kv1.3) in their plasma membranes. More than 30 years ago, patch-clamp studies revealed that the channels play crucial roles in facilitating the calcium influx necessary to trigger lymphocyte activation and proliferation. In addition to selective channel inhibitors that have been developed, we recently showed physiological evidence that drugs such as nonsteroidal anti-inflammatory drugs, antibiotics, and anti-hypertensives effectively suppress the channel currents in lymphocytes, and thus exert immunosuppressive effects. Using experimental animal models, previous studies revealed the pathological relevance between the expression of ion channels and the progression of renal diseases. As an extension, we recently demonstrated that the overexpression of lymphocyte Kv1.3 channels contributed to the progression of chronic kidney disease (CKD) by promoting cellular proliferation and interstitial fibrosis. Together with our in-vitro results, the studies indicated the therapeutic potency of Kv1.3-channel inhibitors in the treatment or the prevention of CKD.

Keywords

Lymphocytes Delayed rectifier K+ channels (Kv1.3) Membrane capacitance (Cm) Immunomodulatory effects Overexpression of Kv1.3 channels Chronic kidney disease (CKD) 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

The author declares that he has no conflict of interest.

References

  1. 1.
    Cahalan MD, Chandy KG, DeCoursey TE, Gupta S (1985) A voltage-gated potassium channel in human T lymphocytes. J Physiol 358:197–237PubMedCentralPubMedGoogle Scholar
  2. 2.
    DeCoursey TE, Chandy KG, Gupta S, Cahalan MD (1984) Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature 307:465–468PubMedGoogle Scholar
  3. 3.
    Lewis RS, Cahalan MD (1995) Potassium and calcium channels in lymphocytes. Annu Rev Immunol 13:623–653PubMedGoogle Scholar
  4. 4.
    Ishida Y, Chused TM (1993) Lack of voltage sensitive potassium channels and generation of membrane potential by sodium potassium ATPase in murine T lymphocytes. J Immunol 151:610–620PubMedGoogle Scholar
  5. 5.
    Deutsch C, Chen LQ (1993) Heterologous expression of specific K+ channels in T lymphocytes: functional consequences for volume regulation. Proc Natl Acad Sci USA 90:10036–10040PubMedCentralPubMedGoogle Scholar
  6. 6.
    Cahalan MD, Wulff H, Chandy KG (2001) Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol 21:235–252PubMedGoogle Scholar
  7. 7.
    Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA (2007) Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes. J Immunol 179:4563–4570PubMedGoogle Scholar
  8. 8.
    Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA et al (2004) K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci 25:280–289PubMedCentralPubMedGoogle Scholar
  9. 9.
    Sugiyama K, Isogai K, Toyama A, Satoh H, Saito K et al (2011) Correlation between the pharmacological efficacy of cyclosporine and tacrolimus as evaluated by the lymphocyte immunosuppressant sensitivity test (LIST) and the MTT assay procedure in patients before and after renal transplantation. Int J Clin Pharmacol Ther 49:145–152PubMedGoogle Scholar
  10. 10.
    Rangaraju S, Chi V, Pennington MW, Chandy KG (2009) Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert Opin Ther Targets 13:909–924PubMedGoogle Scholar
  11. 11.
    Cho JY (2007) Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. Arch Pharm Res 30:64–74PubMedGoogle Scholar
  12. 12.
    Sugiyama K, Shirai R, Mukae H, Ishimoto H, Nagata T et al (2007) Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol 147:540–546PubMedCentralPubMedGoogle Scholar
  13. 13.
    Morikawa K, Zhang J, Nonaka M, Morikawa S (2002) Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J Antimicrob Agents 19:53–59PubMedGoogle Scholar
  14. 14.
    Khan AA, Slifer TR, Araujo FG, Remington JS (1999) Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 11:121–132PubMedGoogle Scholar
  15. 15.
    Palamaras I, Kyriakis K (2005) Calcium antagonists in dermatology: a review of the evidence and research-based studies. Dermatol Online J 11:8PubMedGoogle Scholar
  16. 16.
    Horvath M, Mezey Z, Josfay A, Nanay I, Varsanyi M et al (1991) The effect of some drugs on in vitro cellular immune reactions and on circulating immune complexes in patients with myocardial infarction. J Investig Allergol Clin Immunol 1:404–410PubMedGoogle Scholar
  17. 17.
    Zhou Y, Hancock JF, Lichtenberger LM (2010) The nonsteroidal anti-inflammatory drug indomethacin induces heterogeneity in lipid membranes: potential implication for its diverse biological action. PLoS One 5:e8811PubMedCentralPubMedGoogle Scholar
  18. 18.
    Zuckerman JM (2004) Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin N Am 18:621–649, xi.Google Scholar
  19. 19.
    Chester DW, Herbette LG, Mason RP, Joslyn AF, Triggle DJ et al (1987) Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers. Biophys J 52:1021–1030PubMedCentralPubMedGoogle Scholar
  20. 20.
    Young HS, Skita V, Mason RP, Herbette LG (1992) Molecular basis for the inhibition of 1,4-dihydropyridine calcium channel drugs binding to their receptors by a nonspecific site interaction mechanism. Biophys J 61:1244–1255PubMedCentralPubMedGoogle Scholar
  21. 21.
    Heap GA, van Heel DA (2009) The genetics of chronic inflammatory diseases. Hum Mol Genet 18:R101–R106PubMedGoogle Scholar
  22. 22.
    Kazama I, Maruyama Y, Baba A (2014) Amphipath-induced plasma membrane curvature controls microparticle formation from adipocytes: novel therapeutic implications for metabolic disorders. Med Hypotheses 82:196–198PubMedGoogle Scholar
  23. 23.
    Bohle A, Strutz F, Muller GA (1994) On the pathogenesis of chronic renal failure in primary glomerulopathies: a view from the interstitium. Exp Nephrol 2:205–210PubMedGoogle Scholar
  24. 24.
    Strutz F, Zeisberg M (2006) Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol 17:2992–2998PubMedGoogle Scholar
  25. 25.
    Michimata M, Kazama I, Mizukami K, Araki T, Nakamura Y et al (2003) Urinary concentration defect and limited expression of sodium cotransporter, rBSC1, in a rat model of chronic renal failure. Nephron Physiol 93:34–41Google Scholar
  26. 26.
    Suzuki K, Hatano R, Michimata M, Kazama I, Suzuki M et al (2005) Residual urinary concentrating ability and AQP2 expression in a rat model for chronic renal failure. Nephron Physiol 99:16–22Google Scholar
  27. 27.
    Sanada S, Toyama H, Ejima Y, Matsubara M (2009) Potential for erythropoietin synthesis in kidney of uraemic rat alters depending on severity of renal failure. Nephrology (Carlton) 14:735–742Google Scholar
  28. 28.
    Kumano K, Kogure K, Tanaka T, Sakai T (1986) A new method of inducing experimental chronic renal failure by cryosurgery. Kidney Int 30:433–436PubMedGoogle Scholar
  29. 29.
    Jones SE, Kelly DJ, Cox AJ, Zhang Y, Gow RM et al (2003) Mast cell infiltration and chemokine expression in progressive renal disease. Kidney Int 64:906–913PubMedGoogle Scholar
  30. 30.
    Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G (2005) Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68:237–245PubMedGoogle Scholar
  31. 31.
    Chatenoud L, Dugas B, Beaurain G, Touam M, Drueke T et al (1986) Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity. Proc Natl Acad Sci USA 83:7457–7461PubMedCentralPubMedGoogle Scholar
  32. 32.
    Kaysen GA, Kumar V (2003) Inflammation in ESRD: causes and potential consequences. J Ren Nutr 13:158–160PubMedGoogle Scholar
  33. 33.
    Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD et al (2010) Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 77:550–556PubMedGoogle Scholar
  34. 34.
    Cahalan MD, Chandy KG (2009) The functional network of ion channels in T lymphocytes. Immunol Rev 231:59–87PubMedCentralPubMedGoogle Scholar
  35. 35.
    Grissmer S, Dethlefs B, Wasmuth JJ, Goldin AL, Gutman GA et al (1990) Expression and chromosomal localization of a lymphocyte K+ channel gene. Proc Natl Acad Sci USA 87:9411–9415PubMedCentralPubMedGoogle Scholar
  36. 36.
    Grissmer S, Nguyen AN, Cahalan MD (1993) Calcium-activated potassium channels in resting and activated human T lymphocytes. Expression levels, calcium dependence, ion selectivity, and pharmacology. J Gen Physiol 102:601–630PubMedGoogle Scholar
  37. 37.
    Lewis RS, Cahalan MD (1989) Mitogen-induced oscillations of cytosolic Ca2+ and transmembrane Ca2+ current in human leukemic T cells. Cell Regul 1:99–112PubMedCentralPubMedGoogle Scholar
  38. 38.
    Lewis RS, Ross PE, Cahalan MD (1993) Chloride channels activated by osmotic stress in T lymphocytes. J Gen Physiol 101:801–826PubMedGoogle Scholar
  39. 39.
    Kozak JA, Matsushita M, Nairn AC, Cahalan MD (2005) Charge screening by internal pH and polyvalent cations as a mechanism for activation, inhibition, and rundown of TRPM7/MIC channels. J Gen Physiol 126:499–514PubMedCentralPubMedGoogle Scholar
  40. 40.
    Kazama I, Maruyama Y, Murata Y, Sano M (2012) Voltage-dependent biphasic effects of chloroquine on delayed rectifier K(+)-channel currents in murine thymocytes. J Physiol Sci 62:267–274PubMedGoogle Scholar
  41. 41.
    Kazama I, Maruyama Y, Murata Y (2012) Suppressive effects of nonsteroidal anti-inflammatory drugs diclofenac sodium, salicylate and indomethacin on delayed rectifier K+-channel currents in murine thymocytes. Immunopharmacol Immunotoxicol 34:874–878PubMedGoogle Scholar
  42. 42.
    Kazama I, Maruyama Y (2013) Differential effects of clarithromycin and azithromycin on delayed rectifier K(+)-channel currents in murine thymocytes. Pharm Biol 51:760–765PubMedGoogle Scholar
  43. 43.
    Kazama I, Maruyama Y, Matsubara M (2013) Benidipine persistently inhibits delayed rectifier K(+)-channel currents in murine thymocytes. Immunopharmacol Immunotoxicol 35:28–33PubMedGoogle Scholar
  44. 44.
    Hamilton DL, Beall C, Jeromson S, Chevtzoff C, Cuthbertson DJ et al (2014) Kv1.3 inhibitors have differential effects on glucose uptake and AMPK activity in skeletal muscle cell lines and mouse ex vivo skeletal muscle. J Physiol Sci 64:13–20PubMedGoogle Scholar
  45. 45.
    Han S, Yi H, Yin SJ, Chen ZY, Liu H et al (2008) Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease. J Biol Chem 283:19058–19065PubMedGoogle Scholar
  46. 46.
    Chandy KG, Cahalan M, Pennington M, Norton RS, Wulff H et al (2001) Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants. Toxicon 39:1269–1276PubMedGoogle Scholar
  47. 47.
    Mouhat S, Teodorescu G, Homerick D, Visan V, Wulff H et al (2006) Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain. Mol Pharmacol 69:354–362PubMedGoogle Scholar
  48. 48.
    Orban C, Biro E, Grozdics E, Bajnok A, Toldi G (2013) Modulation of T lymphocyte calcium influx patterns via the inhibition of kv1.3 and ikca1 potassium channels in autoimmune disorders. Front Immunol 4:234PubMedCentralPubMedGoogle Scholar
  49. 49.
    Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M et al (2001) Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 98:13942–13947PubMedCentralPubMedGoogle Scholar
  50. 50.
    Gotzsche PC (1989) Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials 10:31–56PubMedGoogle Scholar
  51. 51.
    Wallace DJ (2010) Advances in drug therapy for systemic lupus erythematosus. BMC Med 8:77PubMedCentralPubMedGoogle Scholar
  52. 52.
    Kazama I, Sasagawa N, Nakajima T (2012) Complete remission of human parvovirus b19 associated symptoms by loxoprofen in patients with atopic predispositions. Case Rep Med 2012:703281PubMedCentralPubMedGoogle Scholar
  53. 53.
    Iniguez MA, Punzon C, Fresno M (1999) Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 163:111–119PubMedGoogle Scholar
  54. 54.
    Hackstein H, Morelli AE, Larregina AT, Ganster RW, Papworth GD et al (2001) Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol 166:7053–7062PubMedGoogle Scholar
  55. 55.
    Gao JX, Issekutz AC (1993) The effect of ebselen on polymorphonuclear leukocyte migration to joints in rats with adjuvant arthritis. Int J Immunopharmacol 15:793–802PubMedGoogle Scholar
  56. 56.
    Villalonga N, David M, Bielanska J, Gonzalez T, Parra D et al (2010) Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels. Biochem Pharmacol 80:858–866PubMedGoogle Scholar
  57. 57.
    Mazzei T, Mini E, Novelli A, Periti P (1993) Chemistry and mode of action of macrolides. J Antimicrob Chemother 31(Suppl C):1–9PubMedGoogle Scholar
  58. 58.
    Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M (1998) Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157:1829–1832PubMedGoogle Scholar
  59. 59.
    Kanoh S, Rubin BK (2010) Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 23:590–615PubMedCentralPubMedGoogle Scholar
  60. 60.
    Price M, Lee SC, Deutsch C (1989) Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes. Proc Natl Acad Sci USA 86:10171–10175PubMedCentralPubMedGoogle Scholar
  61. 61.
    Braunwald E (1982) Mechanism of action of calcium-channel-blocking agents. N Engl J Med 307:1618–1627PubMedGoogle Scholar
  62. 62.
    Birx DL, Berger M, Fleisher TA (1984) The interference of T cell activation by calcium channel blocking agents. J Immunol 133:2904–2909PubMedGoogle Scholar
  63. 63.
    Bacon KB, Westwick J, Camp RD (1989) Potent and specific inhibition of IL-8-, IL-1 alpha- and IL-1 beta-induced in vitro human lymphocyte migration by calcium channel antagonists. Biochem Biophys Res Commun 165:349–354PubMedGoogle Scholar
  64. 64.
    Matsumori A, Nishio R, Nose Y (2010) Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells. Circ J 74:567–571PubMedGoogle Scholar
  65. 65.
    Liu W, Matsumori A (2011) Calcium channel blockers and modulation of innate immunity. Curr Opin Infect Dis 24:254–258PubMedGoogle Scholar
  66. 66.
    Gluais P, Bastide M, Grandmougin D, Fayad G, Adamantidis M (2003) Clarithromycin reduces Isus and Ito currents in human atrial myocytes with minor repercussions on action potential duration. Fundam Clin Pharmacol 17:691–701PubMedGoogle Scholar
  67. 67.
    Volberg WA, Koci BJ, Su W, Lin J, Zhou J (2002) Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 302:320–327PubMedGoogle Scholar
  68. 68.
    Kalman K, Pennington MW, Lanigan MD, Nguyen A, Rauer H et al (1998) ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem 273:32697–32707PubMedGoogle Scholar
  69. 69.
    Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y et al (1999) Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 291:464–473PubMedGoogle Scholar
  70. 70.
    Herbette LG, Chester DW, Rhodes DG (1986) Structural analysis of drug molecules in biological membranes. Biophys J 49:91–94PubMedCentralPubMedGoogle Scholar
  71. 71.
    Kitakaze M, Node K, Minamino T, Asanuma H, Kuzuya T et al (1999) A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol 33:242–249PubMedGoogle Scholar
  72. 72.
    Yamamoto M, Gotoh Y, Imaizumi Y, Watanabe M (1990) Mechanisms of long-lasting effects of benidipine on Ca current in guinea-pig ventricular cells. Br J Pharmacol 100:669–676PubMedCentralPubMedGoogle Scholar
  73. 73.
    Vater W, Kroneberg G, Hoffmeister F, Saller H, Meng K et al (1972) Pharmacology of 4-(2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine, BAY a 1040). Arzneimittelforschung 22:1–14PubMedGoogle Scholar
  74. 74.
    Karasawa A, Kubo K (1988) Calcium antagonistic effects and the in vitro duration of actions of KW-3049, a new 1,4-dihydropyridine derivative, in isolated canine coronary arteries. Jpn J Pharmacol 47:35–44PubMedGoogle Scholar
  75. 75.
    Robe RJ, Grissmer S (2000) Block of the lymphocyte K(+) channel mKv1.3 by the phenylalkylamine verapamil: kinetic aspects of block and disruption of accumulation of block by a single point mutation. Br J Pharmacol 131:1275–1284PubMedCentralPubMedGoogle Scholar
  76. 76.
    Rauer H, Grissmer S (1999) The effect of deep pore mutations on the action of phenylalkylamines on the Kv1.3 potassium channel. Br J Pharmacol 127:1065–1074PubMedCentralPubMedGoogle Scholar
  77. 77.
    DeCoursey TE (1995) Mechanism of K+ channel block by verapamil and related compounds in rat alveolar epithelial cells. J Gen Physiol 106:745–779PubMedGoogle Scholar
  78. 78.
    Yellen G (1998) The moving parts of voltage-gated ion channels. Q Rev Biophys 31:239–295PubMedGoogle Scholar
  79. 79.
    Kazama I, Maruyama Y, Takahashi S, Kokumai T (2013) Amphipaths differentially modulate membrane surface deformation in rat peritoneal mast cells during exocytosis. Cell Physiol Biochem 31:592–600PubMedGoogle Scholar
  80. 80.
    Neher E, Marty A (1982) Discrete changes of cell membrane capacitance observed under conditions of enhanced secretion in bovine adrenal chromaffin cells. Proc Natl Acad Sci USA 79:6712–6716PubMedCentralPubMedGoogle Scholar
  81. 81.
    Kazama I, Maruyama Y, Nakamichi S (2014) Aspirin-induced microscopic surface changes stimulate thrombopoiesis in rat megakaryocytes. Clin Appl Thromb Hemost 20:318–325PubMedGoogle Scholar
  82. 82.
    Kazama I, Endo Y, Toyama H, Ejima Y, Kurosawa S et al (2011) Compensatory thrombopoietin production from the liver and bone marrow stimulates thrombopoiesis of living rat megakaryocytes in chronic renal failure. Nephron Extra 1:147–156PubMedCentralPubMedGoogle Scholar
  83. 83.
    Mahaut-Smith MP, Thomas D, Higham AB, Usher-Smith JA, Hussain JF et al (2003) Properties of the demarcation membrane system in living rat megakaryocytes. Biophys J 84:2646–2654PubMedCentralPubMedGoogle Scholar
  84. 84.
    Fisher JL, Levitan I, Margulies SS (2004) Plasma membrane surface increases with tonic stretch of alveolar epithelial cells. Am J Respir Cell Mol Biol 31:200–208PubMedGoogle Scholar
  85. 85.
    Morris CE, Homann U (2001) Cell surface area regulation and membrane tension. J Membr Biol 179:79–102PubMedGoogle Scholar
  86. 86.
    Suzuki K, Imada T, Gao F, Ma H, Nagata T (1994) Radioautographic study of benidipine hydrochloride. Localization in the mesenteric artery of spontaneously hypertensive rat. Arzneimittelforschung 44:129–133PubMedGoogle Scholar
  87. 87.
    Teisseyre A, Zmonarski SC, Klinger M, Mozrzymas JW, Miekisz S (1996) Patch-clamp study on T-lymphocyte potassium conductance in patients with chronic renal failure. Nephron 72:587–594PubMedGoogle Scholar
  88. 88.
    Grgic I, Wulff H, Eichler I, Flothmann C, Kohler R et al (2009) Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc 41:2601–2606PubMedCentralPubMedGoogle Scholar
  89. 89.
    Hyodo T, Oda T, Kikuchi Y, Higashi K, Kushiyama T et al (2010) Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol 299:F1258–F1269PubMedCentralPubMedGoogle Scholar
  90. 90.
    Platt R, Roscoe MH, Smith FW (1952) Experimental renal failure. Clin Sci (Lond) 11:217–231Google Scholar
  91. 91.
    Morrison AB (1962) Experimentally induced chronic renal insufficiency in the rat. Lab Investig 11:321–332PubMedGoogle Scholar
  92. 92.
    Avioli LV, Scott S, Lee SW, De Luca HF (1969) Intestinal calcium absorption: nature of defect in chronic renal disease. Science 166:1154–1156PubMedGoogle Scholar
  93. 93.
    Bencosme SA, Stone RS, Latta H, Madden SC (1960) Acute tubular and glomerular lesions in rat kidneys after uranium injury. Arch Pathol 69:470–476PubMedGoogle Scholar
  94. 94.
    Fukuda S, Kopple JD (1980) Chronic uremia syndrome in dogs induced with uranyl nitrate. Nephron 25:139–143PubMedGoogle Scholar
  95. 95.
    Allison ME, Wilson CB, Gottschalk CW (1974) Pathophysiology of experimental glomerulonephritis in rats. J Clin Investig 53:1402–1423PubMedCentralPubMedGoogle Scholar
  96. 96.
    Kondo Y, Shigematsu H, Kobayashi Y (1972) Cellular aspects of rabbit Masugi nephritis. II. Progressive glomerular injuries with crescent formation. Lab Investig 27:620–631PubMedGoogle Scholar
  97. 97.
    Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM (1981) Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 241:F85–F93PubMedGoogle Scholar
  98. 98.
    Brenner BM, Meyer TW, Hostetter TH (1982) Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652–659PubMedGoogle Scholar
  99. 99.
    Kohzuki M, Kanazawa M, Liu PF, Kamimoto M, Yoshida K et al (1995) Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors. J Hypertens 13:1785–1790PubMedGoogle Scholar
  100. 100.
    Kazama I, Maruyama Y, Endo Y, Toyama H, Ejima Y et al (2012) Overexpression of delayed rectifier K(+) channels promotes in situ proliferation of leukocytes in rat kidneys with advanced chronic renal failure. Int J Nephrol 2012:581581PubMedCentralPubMedGoogle Scholar
  101. 101.
    El Nahas AM, Anderson S, Harris KPG (eds) (2000) Mechanisms and management of progressive renal failure. Oxford University Press, London, pp 104–145Google Scholar
  102. 102.
    Litjens NH, van Druningen CJ, Betjes MG (2006) Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol 118:83–91PubMedGoogle Scholar
  103. 103.
    Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC (1995) Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int 48:753–760PubMedGoogle Scholar
  104. 104.
    Escobar LI, Martinez-Tellez JC, Salas M, Castilla SA, Carrisoza R et al (2004) A voltage-gated K(+) current in renal inner medullary collecting duct cells. Am J Physiol Cell Physiol 286:C965–C974PubMedGoogle Scholar
  105. 105.
    Abdul M, Hoosein N (2002) Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett 186:99–105PubMedGoogle Scholar
  106. 106.
    Jang SH, Kang KS, Ryu PD, Lee SY (2009) Kv1.3 voltage-gated K(+) channel subunit as a potential diagnostic marker and therapeutic target for breast cancer. BMB Rep 42:535–539PubMedGoogle Scholar
  107. 107.
    Huang S, Zhang CT, Tang JR, Tang J, Cai L, Zhang Z, Zhou MG (2010) Upregulated voltage-gated potassium channel Kv1.3 on CD4+CD28null T lymphocytes from patients with acute coronary syndrome. J Geriatr Cardiol 7:40–46Google Scholar
  108. 108.
    Toldi G, Bajnok A, Dobi D, Kaposi A, Kovacs L et al (2013) The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis. Immunobiology 218:311–316PubMedGoogle Scholar
  109. 109.
    Rus H, Pardo CA, Hu L, Darrah E, Cudrici C et al (2005) The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci USA 102:11094–11099PubMedCentralPubMedGoogle Scholar
  110. 110.
    Schilling T, Eder C (2003) Effects of kinase inhibitors on TGF-beta induced upregulation of Kv1.3 K+ channels in brain macrophages. Pflugers Arch 447:312–315PubMedGoogle Scholar
  111. 111.
    Miyazaki T, Ise M, Seo H, Niwa T (1997) Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl 62:S15–S22PubMedGoogle Scholar
  112. 112.
    Wonderlin WF, Strobl JS (1996) Potassium channels, proliferation and G1 progression. J Membr Biol 154:91–107PubMedGoogle Scholar
  113. 113.
    Jang SH, Choi SY, Ryu PD, Lee SY (2011) Anti-proliferative effect of Kv1.3 blockers in A549 human lung adenocarcinoma in vitro and in vivo. Eur J Pharmacol 651:26–32PubMedGoogle Scholar
  114. 114.
    Lewis RJ, Garcia ML (2003) Therapeutic potential of venom peptides. Nat Rev Drug Discov 2:790–802PubMedGoogle Scholar
  115. 115.
    Judge SI, Lee JM, Bever CT Jr, Hoffman PM (2006) Voltage-gated potassium channels in multiple sclerosis: overview and new implications for treatment of central nervous system inflammation and degeneration. J Rehabil Res Dev 43:111–122PubMedGoogle Scholar
  116. 116.
    Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M et al (2009) Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci USA 106:14518–14523PubMedCentralPubMedGoogle Scholar
  117. 117.
    Kazama I, Baba A, Maruyama Y (2014) HMG-CoA reductase inhibitors pravastatin, lovastatin and simvastatin suppress delayed rectifier K(+)-channel currents in murine thymocytes. Pharmacol Rep 66:712–717PubMedGoogle Scholar
  118. 118.
    Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D et al (2005) Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 68:1254–1270PubMedGoogle Scholar
  119. 119.
    McCloskey C, Jones S, Amisten S, Snowden RT, Kaczmarek LK et al (2010) Kv1.3 is the exclusive voltage-gated K+ channel of platelets and megakaryocytes: roles in membrane potential, Ca2+ signalling and platelet count. J Physiol 588:1399–1406PubMedCentralPubMedGoogle Scholar

Copyright information

© The Physiological Society of Japan and Springer Japan 2014

Authors and Affiliations

  1. 1.Department of Physiology ITohoku University Graduate School of MedicineSendaiJapan

Personalised recommendations